MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
70.31
+3.01
+4.47%
After Hours: 70.38 +0.07 +0.10% 17:40 01/02 EST
OPEN
67.71
PREV CLOSE
67.30
HIGH
70.35
LOW
67.16
VOLUME
2.44M
TURNOVER
--
52 WEEK HIGH
79.50
52 WEEK LOW
47.50
MARKET CAP
8.27B
P/E (TTM)
14.78
1D
5D
1M
3M
1Y
5Y
1D
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025
Barchart · 1d ago
Weekly Report: what happened at HALO last week (1222-1226)?
Weekly Report · 12/29/2025 09:04
Skye Bioscience Signs Collaboration and License Agreement with Halozyme
Reuters · 12/23/2025 21:05
Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside?
Simply Wall St · 12/23/2025 10:20
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
NASDAQ · 12/23/2025 08:53
Weekly Report: what happened at HALO last week (1215-1219)?
Weekly Report · 12/22/2025 09:04
Why Halozyme Therapeutics (HALO) Is Up 8.3% After FDA Nod And Patent Win In Lung Cancer
Simply Wall St · 12/21/2025 11:12
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20/2025 05:44
More
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.